Lansoprazole enteric-coated capsule and preparation method thereof

By using hydroxypropyl methylcellulose capsule shell and capsule coating technology in lansoprazole enteric coating, the problems of poor drug stability and low release are solved, and the high stability and rapid release of the preparation are achieved, reducing the Production costs and process complexity.

CN116251075BActive Publication Date: 2024-11-29WISDOM PHARMACEUTICAL CO LTD +1
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202310334612.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-31
Publication Date
2024-11-29
Estimated Expiration
2043-03-31

AI Technical Summary

Technical Problem

The existing lansoprazole enteric capsules have problems such as poor drug stability, low release, poor reproducibility, complex processes and high production costs.

Method used

The hydroxypropyl methyl cellulose capsule shell is used as the protective layer between the pill containing the pill and the enteric coating to reduce the preparation process and improve the stability and release rate of the preparation through capsule coating technology.

Benefits of technology

The preparation has achieved the enteric capsule preparation with strong acid resistance, fast release speed, high dissolution and good stability, reducing the types and process steps of the auxiliary materials, and improving reproducibility and production efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0005041152220000061
    Figure GDA0005041152220000061
  • Figure GDA0005041152220000071
    Figure GDA0005041152220000071
  • Figure GDA0005041152220000072
    Figure GDA0005041152220000072
Patent Text Reader

Abstract

The present invention belongs to the technical field of pharmaceutical preparations, and discloses a lansoprazole enteric-coated capsule and a preparation method thereof. Lansoprazole enteric-coated capsules include pills, capsule shells and enteric coatings; pills are filled in the capsule shells to form capsule particles; enteric coatings are coated on the surface of capsule particles; the capsule shells are hydroxypropylmethylcellulose capsule shells, and the raw material components of the enteric coatings include, by weight: 24.13-43.37 parts of enteric coating materials, 1.45-6.50 parts of plasticizers, and 2.41-4.34 parts of titanium dioxide; the mass ratio of plasticizer to enteric coating materials is 6-15%. The present invention optimizes and improves the raw material components and preparation process of lansoprazole enteric-coated capsules, and obtains an enteric-coated capsule preparation with strong acid resistance, fast release rate, high dissolution and good stability; compared with conventional preparation processes, there are fewer types of auxiliary materials and process steps, better reproducibility, low production cost and simple and easy operation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a lansoprazole enteric-coated capsule and a preparation method thereof. Background Art

[0002] Among the proton pump inhibitors currently widely used to treat peptic ulcers, there is a class of active substances that are absorbed in the upper part of the small intestine and are unstable in acid. If prepared into conventional preparations, the active substances enter the stomach after oral administration. Since gastric juice is a strongly acidic environment, the active substances are quickly degraded and cannot be absorbed by the human body. In addition, some active substances have a strong irritating effect on the stomach and cannot be taken directly.

[0003] For the above active substances that are sensitive to acid or irritating to the stomach, the conventional solution is to make the drug into an enteric-coated preparation so that the drug is not released in the stomach. After the drug enters the small intestine, the enteric layer dissolves and the drug is released, which effectively avoids the release of the drug in the stomach. Lansoprazole enteric-coated capsules, which are currently on the market, are typical proton pump inhibitors.

[0004] Lansoprazole, chemical name: (±)-2[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]·sulfinyl]benzimidazole. The molecular formula is C 16 H 14 F3N3O2S, molecular weight 369.37, its properties are brownish white crystalline powder. Melting point 166℃, easily soluble in dimethylformamide, soluble in methanol, poorly soluble in anhydrous ethanol, ether, almost insoluble in water. Lansoprazole is a new type of proton pump inhibitor, a benzimidazole substitute developed after omeprazole, a proton pump inhibitor, lansoprazole specifically inhibits H + -K + -ATPase activity, which is a key enzyme in gastric acid production, has an inhibitory effect on basal gastric acid and stress gastric acid secretion caused by stimulation. Lansoprazole is suitable for gastric ulcer, duodenal ulcer, erosive gastroesophageal reflux disease, Helicobacter pylori, and Zollimger-Ellisson syndrome. Lansoprazole tablets and lansoprazole enteric-coated capsules are currently used clinically.

[0005] Lansoprazole is sensitive to acid, oxygen, moisture and heat, and is particularly unstable under acidic conditions. It is easily destroyed in gastric acid. Its bioavailability is improved after it is made into enteric-coated capsules and taken orally.

[0006] The conventional preparation method of lansoprazole enteric-coated capsules currently published by the original research (CN100562317C) is:

[0007] (1) Preparation of pill cores, which include the main drug lansoprazole, fillers, disintegrants, alkalizers, binders, blank pill cores, etc.;

[0008] (2) coating an isolation coating layer, wherein the isolation coating layer is composed of a filler, an adhesive, etc.;

[0009] (3) an enteric coating layer, wherein the enteric coating layer is composed of a pore-forming agent and a film-forming agent;

[0010] (4) Filling capsules.

[0011] The existing disclosed preparation technology of lansoprazole enteric-coated capsules is mainly used to solve the problems of poor stability, low release rate and poor reproducibility of lansoprazole enteric-coated capsules during storage.

[0012] CN100574759C discloses a method for preparing lansoprazole enteric-coated micro-pellets, which can achieve rapid release of the drug and improve bioavailability by adding a certain amount of cosolvent, sodium lauryl sulfate and L-arginine to the drug-containing layer. However, this technical solution may pose certain safety risks to human health due to the addition of a large amount of surfactant to the drug-containing pellets.

[0013] CN102119927B discloses a proton pump inhibitor enteric-coated pellet preparation and a preparation method thereof. According to the conventional preparation method of lansoprazole enteric-coated capsules, two isolation layers are designed, wherein the first isolation layer contains an alkalizer to better improve the stability of the preparation, and the second isolation layer isolates the acidic enteric layer from direct contact with the first isolation layer (alkaline), thereby avoiding a decrease in the acid resistance of the preparation. The types of excipients in this technical solution are basically the same as those of the lansoprazole enteric-coated capsules that have been marketed, but an additional isolation layer is added compared to the original research, which results in a large number of excipients in this component, a cumbersome process, a slow release rate, and incomplete release.

[0014] CN103381268B discloses a solid pharmaceutical composition containing a proton pump inhibitor, wherein the active ingredient is reduced in particle size by an appropriate method in the presence of at least one inactive ingredient to improve the drug release rate and bioavailability. Compared with other existing technologies, this technical solution introduces a pulverization process, which has certain requirements on the particle size after pulverization, increases the difficulty of the production process, and is not conducive to the control of production costs.

[0015] CN103356489B discloses a proton pump inhibitor enteric-coated micro-pellet and its preparation and preparation method. The preparation includes a blank pellet core, a drug-carrying layer, a protective layer, an isolation layer, a water-blocking layer and an enteric layer, wherein the water-blocking layer uses corn protein as a water-blocking material, which can effectively avoid the problem of moisture absorption of the drug during storage and the problem of "burst release effect" in water (dissolution medium), thereby improving the quality and stability of the product. However, the preparation has many types of auxiliary materials, complicated processes and high production costs.

[0016] CN104523641B discloses a lansoprazole enteric-coated preparation and a preparation method thereof. The preparation is prepared with lansoprazole as the main drug and is coated with three layers, wherein the three coating layers are respectively: an alkaline protective layer, an isolation layer, and an enteric layer from the inside to the outside. The alkaline protective layer includes two isolation layers, the purpose of which is to improve the stability of lansoprazole and reduce the phenomenon of deterioration during storage. This technical solution also has the problems of complicated procedures and high production costs.

[0017] Therefore, the existing lansoprazole enteric-coated capsules have poor drug stability, and the long-term placement process easily leads to degradation impurities and unqualified in vitro release, slow in vitro release, poor reproducibility, complex process, and high production cost. The conventional preparation process includes at least four process steps: preparation of pills, preparation of isolated pills, preparation of enteric-coated pills, and capsule filling. Among them, the preparation of enteric-coated pills adopts micro-pill coating technology, and the reproducibility and uniformity of coating are difficult to control well. At the same time, the lansoprazole enteric-coated capsules currently on the market all use gelatin capsule shells, but the gelatin capsule shell has a high moisture content. During the long-term placement process, the moisture of the gelatin capsule shell will migrate to the inside of the micro-pill, resulting in poor stability of the preparation. At the same time, as the gelatin capsule shell loses moisture, the brittleness of the capsule shell increases, which has a greater impact on dissolution. Summary of the invention

[0018] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention proposes a lansoprazole enteric-coated capsule and a preparation method thereof. The present invention optimizes and improves the raw material components and preparation process of the lansoprazole enteric-coated capsule to obtain an enteric-coated capsule preparation with strong acid resistance, fast release rate, high dissolution and good stability; compared with the conventional preparation process, the types of auxiliary materials and process steps are fewer, the reproducibility is better, the production cost is low and it is simple and easy to operate.

[0019] In order to solve the above technical problems, the first aspect of the present invention provides a lansoprazole enteric-coated capsule, comprising a pill, a capsule shell and an enteric coating; the pill is filled in the capsule shell to form capsule particles; the enteric coating is coated on the surface of the capsule particles; the capsule shell is a hydroxypropyl methylcellulose capsule shell, the capsule shell is a hydroxypropyl methylcellulose (abbreviated as: HPMC) capsule shell, and the raw material components of the enteric coating include, by weight: 24.13-43.37 parts of enteric coating material, 1.45-6.50 parts of plasticizer, and 2.41-4.34 parts of titanium dioxide; the mass ratio of the plasticizer to the enteric coating material is 6-15%.

[0020] Specifically, the present invention reduces the preparation process of enteric-coated capsules, adopts a capsule shell as a protective layer between the drug-containing pills and the enteric coating, and adopts a hydroxypropyl methylcellulose capsule shell, which can effectively improve the stability of the preparation while maintaining the multi-unit release mechanism of the micro-pills, compared with the gelatin capsules used in the lansoprazole enteric-coated capsules that have been on the market.

[0021] At the same time, in order to avoid the degradation of active substances in the preparation by contact with gastric acid after taking, the present invention adopts capsule coating technology to coat the capsule particles with an enteric layer. Compared with conventional micro-pellet coating, there is no need to consider the size of the micro-pellets, avoiding the mistakes or defects in the preparation of the enteric coating of individual small pellets that affect the drug release behavior of the overall preparation, so the reproducibility and consistency of the drug release law are better; and compared with tablets, the characteristics of multi-unit release of micro-pellets are retained. After the capsule passes through the stomach, under the influence of the pH of the small intestine, the drug is not blocked by the isolation layer after the enteric coating film and the capsule shell dissolve, and the drug can be released more quickly and fully.

[0022] In addition, the enteric coating of the present invention uses enteric coating materials, plasticizers and titanium dioxide as raw materials, wherein: the amount of the enteric coating material directly affects the thickness of the enteric coating film of the preparation and the sealing effect at the capsule shell joint, thereby affecting the acid resistance and release rate of the preparation itself; the plasticizer can reduce the glass transition temperature of the enteric coating material, thereby affecting the film-forming property of the enteric film; titanium dioxide is a light-shielding agent. The present invention controls the amount range of each raw material to obtain the best acid resistance and dissolution rate of the preparation.

[0023] Preferably, the raw material components of the enteric coating include, by weight: 33.75-43.36 parts of enteric coating material, 2.03-6.50 parts of plasticizer, and 3.34-4.34 parts of titanium dioxide.

[0024] Preferably, the mass ratio of the plasticizer to the enteric coating material is 8-12%.

[0025] As a further improvement of the above scheme, the raw material components containing the pills include, by weight: 30 parts of lansoprazole, 50-100 parts of sucrose pill cores, 20-60 parts of sucrose powder, 5-15 parts of corn starch, 10-30 parts of pH regulator, and 10-30 parts of low-substituted hydroxypropyl cellulose.

[0026] Preferably, the raw material components containing the pills include, by weight: 30 parts of lansoprazole, 70-90 parts of sucrose pill cores, 40-60 parts of sucrose powder, 8-12 parts of corn starch, 20-30 parts of pH regulator, and 20-30 parts of low-substituted hydroxypropyl cellulose.

[0027] As a further improvement of the above solution, the particle size of the sucrose pellet core is in the range of 0.5-1.0 mm.

[0028] Preferably, the particle size of the sucrose sphere core is in the range of 0.6-0.71 mm.

[0029] As a further improvement of the above scheme, the pH adjuster is selected from any one of sodium carbonate, sodium bicarbonate, light magnesium carbonate, heavy magnesium carbonate, sodium hydroxide, disodium hydrogen phosphate, and potassium hydrogen phosphate.

[0030] Preferably, the pH adjuster is selected from any one of sodium bicarbonate, light magnesium carbonate and heavy magnesium carbonate.

[0031] As a further improvement of the above scheme, the enteric coating material is selected from any one of methacrylic acid copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl phthalate, and styrene maleic acid copolymer.

[0032] Preferably, the enteric coating material is selected from methacrylic acid copolymers.

[0033] As a further improvement of the above solution, the plasticizer is selected from any one of polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 8000, triethyl citrate (abbreviated as: TEC), and triethyl glycerol.

[0034] Preferably, the plasticizer is selected from polyethylene glycol 6000 or triethyl citrate.

[0035] The second aspect of the present invention provides a method for preparing lansoprazole enteric-coated capsules, wherein the method is used to prepare the lansoprazole enteric-coated capsules according to the first aspect of the present invention, and comprises the following steps:

[0036] (1) preparing a pill containing the drug;

[0037] (2) filling the drug-containing pills into a hydroxypropylmethylcellulose capsule shell to obtain capsule particles;

[0038] (3) After the plasticizer is dissolved, titanium dioxide is added for dispersion, and then added to the aqueous dispersion solution of the enteric coating material, sieved to obtain an enteric coating solution; the enteric coating solution is sprayed onto the surface of the capsule particles for capsule coating, and dried to obtain the lansoprazole enteric capsules.

[0039] As a further improvement of the above scheme, the preparation method of the lansoprazole enteric-coated capsules comprises the following steps:

[0040] (1) Preparation of pills containing medicine:

[0041] A. Slowly add hydroxypropyl cellulose to purified water, stir until completely dissolved, and prepare a 2% (w / w) hydroxypropyl cellulose aqueous solution as a binder for standby use; the binder is prepared in an amount of 50% of the weight of the powder for pills, and the actual amount is based on the amount used at the end of pill making;

[0042] B. premixing lansoprazole, sucrose powder, corn starch, light magnesium carbonate and low-substituted hydroxypropyl cellulose, sieving through a 120-mesh sieve, and then transferring to a fixed hopper mixer for mixing to obtain a powder material;

[0043] C. Put the sucrose pellet core into a centrifugal granulator, spray the binder prepared in step A, and evenly sprinkle the powder prepared in step B on the surface of the sucrose pellet core;

[0044] D. The pellets obtained by centrifugal granulation are dried in a 45°C oven for at least 16 h, and then sieved to obtain pellets with a mesh size of 16-30 to obtain the drug-containing pellets.

[0045] (2) Capsule filling:

[0046] E. Calculate the actual unit dose according to the drug content, and fill the qualified drug-containing pills into the hydroxypropyl methylcellulose capsule shell through a capsule filling machine to obtain capsule particles;

[0047] (3) Capsule coating:

[0048] F. Add triethyl citrate to purified water and stir to dissolve, then add titanium dioxide to evenly disperse, then slowly add to the Eudragit L30D-55 aqueous dispersion solution, sieve through 100 mesh to obtain an enteric coating solution;

[0049] G. Put the capsules prepared in step E into a film coating machine, set appropriate air inlet temperature, air volume and pan speed, spray the enteric coating solution prepared in step F evenly onto the surface of the capsules, and then dry at 45° C. for 30-60 min to obtain the lansoprazole enteric capsules.

[0050] Specifically, when preparing the drug-containing pills, the present invention adopts a powder layering process, uses a sucrose pill core as a substrate, a mixture containing active substances and inactive substances as a powder feed material, and a hydroxypropyl cellulose aqueous solution as a binder, and prepares the upper drug pills with a certain strength in a centrifugal granulation pill making machine; uses a hydroxypropyl methylcellulose capsule shell for capsule filling, which serves as a protective layer between the drug-containing layer and the enteric layer to improve the stability of the preparation; and uses a film coating machine to perform enteric coating on the capsule particles, with the coating weight gain being 15-25%, so as to obtain a lansoprazole enteric capsule preparation which has no release in the stomach, fast release in the intestine, and good stability.

[0051] As a further improvement of the above solution, during the capsule coating process, the rotation speed of the pan is 5-15 rpm. Preferably, the rotation speed of the pan is 7-12 rpm.

[0052] Specifically, the pan speed affects the flow state of the capsule in the coating pan. A too low pan speed can easily cause the capsule shell to flip unsmoothly in the coating pan, resulting in sticking to the pan or uneven coating. A too high pan speed can easily cause the capsule shell to collide more severely, resulting in rupture of the capsule shell or uneven coating.

[0053] As a further improvement of the above scheme, during the capsule coating process, the air intake frequency / exhaust frequency is 600-1500 Hz, preferably, the air intake frequency / exhaust frequency is 800-1200 Hz.

[0054] Specifically, the air intake frequency / exhaust frequency affects the coating effect of the capsule in the coating pan. Too low air intake frequency / exhaust frequency can easily lead to too low drying rate of the capsule shell in the coating pan, causing the capsule to stick or dissolve. Too high air intake frequency / exhaust frequency can easily lead to spray drying loss of the coating liquid, resulting in low coating efficiency.

[0055] As a further improvement of the above solution, during the capsule coating process, the atomization pressure is 0.2-1.0 bar. Preferably, the atomization pressure is 0.3-0.8 bar.

[0056] Specifically, the atomization pressure affects the atomization effect of the coating liquid and thus affects the coating effect. If the atomization pressure is too low, it is easy to cause the atomized droplets to be too large, thereby causing the capsule shell to stick or dissolve; if the atomization pressure is too high, it is easy to cause the atomized droplets to be too fine, resulting in spray drying loss of the coating liquid, and it is easy to spray onto the inner wall of the coating pan, resulting in a decrease in coating efficiency. At the same time, compared with ordinary tablet coating, capsule coating is hollow inside the capsule. If the atomization pressure is too high, the impact force on the capsule shell surface will be greater, which will easily lead to the risk of collapse and deformation of the capsule shell, resulting in a poor coating effect.

[0057] As a further improvement of the above solution, during the capsule coating process, the material temperature is 28-40°C. Preferably, the material temperature is 28-35°C.

[0058] Specifically, the control of material temperature is a key process parameter for capsule coating, which will affect the coating effect and the product quality of enteric-coated capsules. If the material temperature is controlled too low, the corresponding drying effect will be weak and the capsule shell will easily stick; if the material temperature is controlled too high, the capsule coating effect may deteriorate and affect the final acid resistance of the product.

[0059] Compared with the prior art, the above technical solution of the present invention has at least the following technical effects or advantages:

[0060] (1) The present invention reduces the preparation process of enteric-coated capsules and uses hydroxypropyl methylcellulose capsule shell as a protective layer between the pills and the enteric coating. While maintaining the multi-unit release mechanism of the pellets, the stability of the preparation is improved. Compared with conventional pellet coating technology, the in vitro release rate is significantly increased, the release is safer, and the production efficiency is improved.

[0061] (2) The present invention adopts a capsule coating process to prevent the active ingredients of the preparation from being degraded by contact with gastric acid after administration. Compared with conventional micro-pellet coating technology, it avoids the mistakes or defects in the preparation of enteric coating of individual small pellets that affect the drug release behavior of the overall preparation, so the reproducibility and consistency of the drug release pattern are better; at the same time, it avoids the problem of coating uniformity caused by the rough surface of the micro-pellets. The surface of the capsule shell is smooth and the adhesion between the coating material and the capsule shell is stronger, so the capsule coating can improve the acid resistance uniformity and strength of the preparation. DETAILED DESCRIPTION

[0062] The present invention is described in detail below in conjunction with the examples, so that the technical personnel of the relevant technical field can understand the present invention. It is necessary to point out here that the examples are only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. The non-essential improvements and adjustments made to the present invention by the skilled person in the relevant field according to the above invention content should still belong to the scope of protection of the present invention. At the same time, the raw materials mentioned below that are not described in detail are all commercially available products; the process steps or preparation methods that are not mentioned in detail are all process steps or preparation methods known to those skilled in the art.

[0063] The raw material components of the lansoprazole enteric-coated capsules of the following examples are shown in Table 1, wherein the particle size of the sucrose pellet core is 0.5-1.0 mm.

[0064] Table 1: Raw material composition of Lansoprazole Enteric Coated Capsules

[0065]

[0066]

[0067] The proportion of excipients in the pill-containing component in Table 1 determines the final capsule filling amount, and the filling amount affects the size of the activity space of the pills in the capsule shell. Since capsule coating is required later, if the capsule activity space is too large, it may cause the pills to be damaged during the coating process, thus affecting the final quality of the product. In addition, when the number of micro-pellets inside the capsule shell is small, it may also cause the capsule shell to not turn smoothly in the coating machine, resulting in uneven coating film.

[0068] The present invention is described by taking No. 1 HPMC capsule shell as an example, and the technology can still be applied to other types of hydroxypropyl methylcellulose capsule shells.

[0069] Example 1

[0070] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0071] (1) Preparation of pills containing 125 mg of drug per capsule:

[0072] Hydroxypropyl cellulose (2.25 g) was slowly added to purified water (110.25 g), stirred until completely dissolved, and a 2% (w / w) concentration of hydroxypropyl cellulose aqueous solution was prepared as a binder for standby use. Lansoprazole, sucrose powder, corn starch, light magnesium carbonate and low-substituted hydroxypropyl cellulose were pre-mixed and sieved through a 120-mesh screen, and then transferred to a fixed hopper mixer for mixing for 10 minutes to obtain a powder material. The sucrose pellet core was put into a centrifugal granulator, and while spraying a 2% hydroxypropyl cellulose aqueous solution, the powder material was evenly powdered and coated on the surface of the sucrose pellet core. The pellets obtained by centrifugal granulation were dried in a 45°C oven for at least 16 hours, and then sieved to obtain pellets between 16-30 mesh to obtain drug-containing pills, the raw material components of which are shown in Table 2.

[0073] Table 2: Raw material composition table of pills in Example 1

[0074]

[0075]

[0076] (2) Capsule filling:

[0077] The qualified drug-containing pills obtained in step (1) are filled into hydroxypropylmethylcellulose capsule shells by a capsule filling machine to obtain capsule particles, the raw material components of which are shown in Table 3.

[0078] Table 3: Raw material composition of capsule particles of Example 1

[0079] raw material Component (g) Containing pills 375 Hydroxypropyl methylcellulose capsule shell 25 (3000 tablets) Total 400 (3000 tablets)

[0080] Theoretical batch size is 3000 capsules, each hydroxypropyl methylcellulose capsule shell weight is about 83mg, 3000 blank capsule shell weight

[0081] =83mg×3000÷1000=25g

[0082] (3) Capsule coating:

[0083] Triethyl citrate was added to purified water (193.07 g) and stirred to dissolve, and then titanium dioxide was added to uniformly disperse. The prepared solution was slowly added to a 30% (w / w) methacrylic acid copolymer aqueous dispersion solution (241.33 g), and sieved through 100 mesh to obtain a 20% (w / w) enteric coating solution. The capsule particles were put into a film coating machine, and the pot speed was set to 5-12 rpm, the air inlet temperature was 38-50° C., the air inlet frequency was 600-1500 Hz, the exhaust frequency was 600-1500 Hz, the atomization pressure was 0.3-0.8 bar, and the material temperature was maintained at 28-35° C. The enteric coating solution was uniformly sprayed onto the surface of the capsule particles, and then dried at 45° C. for 30-60 min to obtain the lansoprazole enteric capsules of the present embodiment, and the raw material components thereof are shown in Table 4.

[0084] Table 4: Raw material composition of enteric-coated capsules of Example 1

[0085] raw material Component (g) Capsules 400 (3000 tablets) Methacrylic acid copolymer 72.4 Triethyl citrate 10.9 Titanium Dioxide 7.2 Total 490.5 Theoretical coating weight gain 22.63%

[0086] Example 2

[0087] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0088] Preparation of pellets containing 265 mg of a single capsule:

[0089] Hydroxypropyl cellulose (4.95 g) was slowly added to purified water (242.55 g), stirred until completely dissolved, and a 2% (w / w) concentration of hydroxypropyl cellulose aqueous solution was prepared as a binder for standby use. Lansoprazole, sucrose powder, corn starch, light magnesium carbonate and low-substituted hydroxypropyl cellulose were pre-mixed and sieved through a 120-mesh screen, and then transferred to a fixed hopper mixer for mixing for 10 minutes to obtain a powder material. The sucrose pellet core was put into a centrifugal granulator, and while spraying a 2% hydroxypropyl cellulose aqueous solution, the powder material was evenly powdered and coated on the surface of the sucrose pellet core. The pellets obtained by centrifugal granulation were dried in a 45°C oven for at least 16 hours, and then sieved to obtain pellets between 16-30 mesh to obtain pills containing medicines, and the raw material components are shown in Table 5.

[0090] Table 5: Raw material composition table of Example 2 containing pills

[0091] raw material Component (g) Lansoprazole 90 Sucrose pellets 300 Sucrose powder 180 Corn starch 45 Light magnesium carbonate 90 Low substituted hydroxypropyl cellulose 90 Total 795

[0092] Since the theoretical batch size of Example 2 and Example 1 is unchanged, the number of capsule filling particles is unchanged, and in order to maintain the same coating time and enteric layer thickness, the capsule filling and coating component processes of Example 2 are consistent with those of Example 1.

[0093] Example 3

[0094] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0095] Preparation of single capsule containing 203.67 mg pellets:

[0096] Hydroxypropyl cellulose (3.61 g) was slowly added to purified water (176.89 g), stirred until completely dissolved, and a 2% (w / w) concentration of hydroxypropyl cellulose aqueous solution was prepared as a binder for standby use. Lansoprazole, sucrose powder, corn starch, light magnesium carbonate and low-substituted hydroxypropyl cellulose were pre-mixed and sieved through a 120-mesh screen, and then transferred to a fixed hopper mixer for mixing for 10 minutes to obtain a powder material. The sucrose pellet core was put into a centrifugal granulator, and while spraying a 2% hydroxypropyl cellulose aqueous solution, the powder material was evenly powdered and coated on the surface of the sucrose pellet core. The pellets obtained by centrifugal granulation were dried in a 45°C oven for at least 16 hours, and then sieved to obtain pellets between 16-30 mesh to obtain drug-containing pills, the raw material components of which are shown in Table 6.

[0097] Table 6: Raw material composition table of Example 3 containing pills

[0098]

[0099]

[0100] Since the theoretical batch size of Example 3 is the same as that of Example 1, the number of capsules filled remains unchanged. To maintain the same coating time and enteric layer thickness, the capsule filling and coating component processes of Example 3 are consistent with those of Example 1, and the theoretical coating weight gain is 15%.

[0101] Example 4

[0102] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0103] Preparation of pellets containing 100 mg of drug per capsule:

[0104] Hydroxypropyl cellulose (2g) was slowly added to purified water (98g), stirred until completely dissolved, and a 2% (w / w) concentration of hydroxypropyl cellulose aqueous solution was prepared as a binder for standby use. Lansoprazole, sucrose powder, corn starch, light magnesium carbonate and low-substituted hydroxypropyl cellulose were pre-mixed and sieved through a 120-mesh screen, and then transferred to a fixed hopper mixer for mixing for 10 minutes to obtain a powder material. The sucrose pellet core was put into a centrifugal granulator, and while spraying a 2% hydroxypropyl cellulose aqueous solution, the powder material was evenly powdered and coated on the surface of the sucrose pellet core. The pellets obtained by centrifugal granulation were dried in a 45°C oven for at least 16 hours, and then sieved to obtain pellets between 16-30 mesh to obtain pills containing medicines, and the raw material components are shown in Table 7.

[0105] Table 7: Example 4 contains the raw material composition of the pill

[0106] raw material Component (g) Lansoprazole 90 Sucrose pellets 100 Sucrose powder 50 Corn starch 12 Light magnesium carbonate 24 Low substituted hydroxypropyl cellulose 24 Total 300

[0107] Since the theoretical batch size of Example 4 and Example 1 is unchanged, the number of capsules filled is unchanged, and in order to maintain the same coating time and enteric layer thickness, the capsule filling and coating component processes of Example 4 are consistent with those of Example 1.

[0108] Comparative Example 1

[0109] The difference between Comparative Example 1 and Example 1 is that Comparative Example 1 uses No. 1 gelatin hollow capsule shell to replace the hydroxypropyl methylcellulose capsule shell of Example 1. Wherein: the raw material components of the capsule particles are shown in Table 8.

[0110] Table 8: Raw material composition of capsule particles of comparative example 1

[0111] raw material Component (g) Containing pills 375 Gelatin empty capsule shell 22.5 (3000 tablets) Total 397.5 (3000 tablets)

[0112] Theoretical batch size is 3000 capsules, each empty gelatin capsule shell weighs about 75 mg, and 3000 blank capsule shells weigh

[0113] =75mg×3000÷1000=22.5g.

[0114] Performance Test 1

[0115] 1. Pellets crushing

[0116] 20 lansoprazole enteric-coated capsules prepared in Examples 1-4 were taken respectively, the contents were collected, the appearance of the drug-containing pellets was observed, and the pellets were passed through a 30-mesh sieve after being weighed. The passing rate of the crushed pellets was counted, and the results are shown in Table 9.

[0117] Table 9: Crushing of the micropellets of Examples 1-4

[0118]

[0119] As shown in Table 9, the breakage rates of the micro-pellets in Examples 1-3 are relatively low, and the breakage rate of the micro-pellets in Example 4 is greater than 3.0%, indicating that the capsules with different filling amounts have a larger space for collision between the micro-pellets during the coating process, and are more easily damaged. At the same time, the surface of the enteric-coated capsule in Example 4 is not completely coated, which is presumably due to the small number of micro-pellets inside, and the capsule particles are not smoothly turned in the coating pan. The drug-containing pills of 125-265 mg are loaded in the No. 1 capsule shell, and the enteric coating effect is good.

[0120] 2. Dissolution rate test

[0121] The dissolution rate test of the present invention is carried out according to the dissolution and release determination method (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0931 Second Method), using 900 mL of pH 6.8 phosphate buffer solution as the dissolution medium, the rotation speed is 50 revolutions per minute, and the dissolution rate of the sample at different times is determined according to the high performance liquid chromatography method (General Rules 0512). The lansoprazole enteric-coated capsules of Examples 1-4 and the lansoprazole enteric-coated capsules (trade name) already marketed by Tianjin Takeda Pharmaceutical Co., Ltd. ) at different time dissolution rates are shown in Table 10.

[0122] Table 10: Lansoprazole enteric-coated capsules of Examples 1-4 and Comparison of dissolution at different times

[0123]

[0124]

[0125] As shown in Table 10, in pH 6.8 phosphate buffer, the dissolution rates at different time points in Examples 1-3 are basically the same, and the dissolution rate of Example 4 is faster than that of Examples 1-3. The reason may be that the pellets are broken more during the coating process, resulting in an increase in the contact surface of the pellets in the dissolution medium and thus an accelerated dissolution rate. Although the dissolution rate of Example 4 is increased compared to that of Examples 1-3, it may be beneficial for the rapid release and absorption of the pellets in the upper intestinal tract and improve bioavailability, but the pellet crushing is an uncontrollable process, which is not conducive to product quality control, so the pellet component in Example 4 is not an optional range.

[0126] contrast The release rate of Examples 1-3 is faster and the release is almost complete. Since lansoprazole is mainly absorbed in the upper small intestine, faster release is beneficial to improving the bioavailability in vivo.

[0127] 3. Stability test

[0128] The lansoprazole enteric-coated capsule samples of Examples 1-4 and Comparative Example 1 were respectively placed in 60 mL high-density polyethylene bottles, the bottle mouths were heat-sealed with gaskets and the caps were screwed, and the bottles were placed in a 60° C. high-temperature stabilization box. The complete package was placed in the same stability box to examine the stability of the samples for 5 days, 10 days, 20 days and 30 days. Among them: the appearance of the stability content, stability content, stability-related substances and stability dissolution are shown in Tables 11-14 respectively.

[0129] Table 11: Lansoprazole enteric-coated capsules of Examples 1-4 and Comparative Example 1 and Stability Content Appearance Comparison Table

[0130]

[0131] Table 12: Lansoprazole enteric-coated capsules of Examples 1-4 and Comparative Example 1 and Stability Content Comparison Table

[0132]

[0133]

[0134] Table 13: Lansoprazole enteric-coated capsules of Examples 1-4 and Comparative Example 1 and Comparison table of stability related substances

[0135]

[0136] Table 14: Lansoprazole enteric-coated capsules of Examples 1-4 and Comparative Example 1 and Stability Dissolution Comparison Table

[0137]

[0138] The stability results in Tables 11-14 show that the color of the pellets in Example 1-4 did not change significantly during the high temperature 60°C stability process, and the dissolution and content were basically the same as on day 0; and the lansoprazole enteric-coated capsules that have been marketed After 20 days, the color of the pellets changed significantly, the content showed a clear downward trend, and the impurities increased significantly. In contrast, in Example 1-4, the use of the HPMC capsule shell as the protective layer for the drug-containing layer and the enteric layer can significantly improve the stability of the preparation.

[0139] At the same time, compared with the comparative example 1 using the gelatin hollow capsule shell, the embodiments 1-4 of the present invention using the HPMC capsule shell as the protective layer have obvious advantages in terms of stability including content, related substances and dissolution. The water content of the ordinary gelatin hollow capsule shell is generally greater than 12%, and the water content of the HPMC capsule shell is generally less than 5%. Therefore, during the stability process, the water content of the gelatin hollow capsule shell is easy to migrate to the pill-containing local high humidity environment, resulting in aggravated degradation of the active substance. In addition, the gelatin hollow capsule shell becomes more brittle after dehydration and is prone to cross-linking, resulting in slower dissolution.

[0140] Therefore, the raw material components of the pill-containing drug of the present invention include, by weight, 30 parts of lansoprazole, 50-100 parts of sucrose pill cores, 20-60 parts of sucrose powder, 5-15 parts of corn starch, 10-30 parts of pH regulator, 10-30 parts of low-substituted hydroxypropyl cellulose, and the total weight of the pills is 125-265 parts.

[0141] Example 5

[0142] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0143] (1) Preparation of pills containing 203.67 mg of drug per capsule:

[0144] According to the raw material components and preparation process of the medicine-containing pills in Example 3, the corresponding medicine-containing pills were prepared.

[0145] (2) Capsule filling:

[0146] The qualified pills containing the drug are filled into the hydroxypropyl methylcellulose capsule shell by a capsule filling machine to obtain capsule particles, the raw material components of which are shown in Table 15.

[0147] Table 15: Raw material composition of capsule particles of Example 5

[0148] raw material Component (g) Containing pills 611 Hydroxypropyl methylcellulose capsule shell 25 (3000 tablets) Total 636 (3000 tablets)

[0149] Theoretical batch size is 3000 capsules, each hydroxypropyl methylcellulose capsule shell weight is about 75mg, 3000 blank capsule shell weight

[0150] =75mg×3000÷1000=25g.

[0151] (3) Capsule coating: (In each enteric-coated capsule, the amount of methacrylic acid copolymer is 24.13 mg)

[0152] Triethyl citrate was added to purified water (193.07 g) and stirred to dissolve, and then titanium dioxide was added to uniformly disperse. The prepared solution was slowly added to a 30% (w / w) methacrylic acid copolymer aqueous dispersion solution (241.33 g), and sieved through 100 mesh to obtain a 20% (w / w) enteric coating solution. The capsule particles were put into a film coating machine, and the pot speed was set to 5-12 rpm, the air inlet temperature was 38-50° C., the air inlet frequency was 600-1500 Hz, the exhaust frequency was 600-1500 Hz, the atomization pressure was 0.3-0.8 bar, and the material temperature was maintained at 28-35° C. The enteric coating solution was uniformly sprayed onto the surface of the capsule particles, and then dried at 45° C. for 30-60 min to obtain the lansoprazole enteric capsules of the present embodiment, and the raw material components thereof are shown in Table 16.

[0153] Table 16: Raw material composition of enteric-coated capsules of Example 5

[0154] raw material Component (g) Capsules 636 (3000 tablets) Methacrylic acid copolymer 72.4 Triethyl citrate 10.9 Titanium Dioxide 7.2 Total 726.5 Theoretical coating weight gain 14.23%

[0155] Example 6

[0156] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0157] The preparation process of the pills and capsule filling is the same as that in Example 5.

[0158] Capsule coating: (In each enteric-coated capsule, the amount of methacrylic acid copolymer is 33.77 mg)

[0159] Triethyl citrate was added to purified water (270.03 g) and stirred to dissolve, and then titanium dioxide was added to uniformly disperse. The prepared solution was slowly added to a 30% (w / w) methacrylic acid copolymer aqueous dispersion solution (337.67 g), and sieved through 100 mesh to obtain a 20% (w / w) enteric coating solution. The capsule particles were put into a film coating machine, and the pot speed was set to 5-12 rpm, the air inlet temperature was 38-50° C., the air inlet frequency was 600-1500 Hz, the exhaust frequency was 600-1500 Hz, the atomization pressure was 0.3-0.8 bar, and the material temperature was maintained at 28-35° C. The enteric coating solution was evenly sprayed onto the surface of the capsule particles, and then dried at 45° C. for 30-60 min to obtain the lansoprazole enteric capsules of the present embodiment, and the raw material components thereof are shown in Table 17.

[0160] Table 17: Raw material composition of enteric-coated capsules of Example 6

[0161] raw material Component (g) Capsules 636 (3000 tablets) Methacrylic acid copolymer 101.3 Triethyl citrate 15.2 Titanium Dioxide 10.1 Total 762.6 Theoretical coating weight gain 19.91%

[0162] Example 7

[0163] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0164] The preparation process of the pills and capsule filling is the same as that in Example 5.

[0165] Capsule coating: (In each enteric-coated capsule, the amount of methacrylic acid copolymer is 43.37 mg)

[0166] Triethyl citrate was added to purified water (347.17 g) and stirred to dissolve, and then titanium dioxide was added to uniformly disperse. The prepared solution was slowly added to a 30% (w / w) methacrylic acid copolymer aqueous dispersion solution (433.33 g), and sieved through 100 mesh to obtain a 20% (w / w) enteric coating solution. The capsule particles were put into a film coating machine, and the pot speed was set to 5-12 rpm, the air inlet temperature was 38-50° C., the air inlet frequency was 600-1500 Hz, the exhaust frequency was 600-1500 Hz, the atomization pressure was 0.3-0.8 bar, and the material temperature was maintained at 28-35° C. The enteric coating solution was uniformly sprayed onto the surface of the capsule particles, and then dried at 45° C. for 30-60 min to obtain the lansoprazole enteric-coated capsules of the present embodiment, and the raw material components thereof are shown in Table 18.

[0167] Table 18: Raw material composition of enteric-coated capsules of Example 7

[0168]

[0169]

[0170] Comparative Example 2

[0171] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0172] The preparation process of the pills and capsule filling is the same as that in Example 5.

[0173] Capsule coating: (In each enteric-coated capsule, the amount of methacrylic acid copolymer is 53.4 mg)

[0174] Triethyl citrate was added to purified water (427g) and stirred to dissolve, and then titanium dioxide was added to uniformly disperse. The prepared solution was slowly added to a 30% (w / w) methacrylic acid copolymer aqueous dispersion solution (534g), and sieved through 100 mesh to obtain a 20% (w / w) enteric coating solution. The capsule particles were put into a film coating machine, and the pot speed was set to 5-12rpm, the air inlet temperature was 38-50°C, the air inlet frequency was 600-1500Hz, the exhaust frequency was 600-1500Hz, the atomization pressure was 0.3-0.8bar, and the material temperature was maintained at 28-35°C. The enteric coating solution was evenly sprayed onto the surface of the capsule particles, and then dried at 45°C for 30-60min to obtain the lansoprazole enteric capsules of this comparative example, and the raw material components thereof are shown in Table 19.

[0175] Table 19: Raw material composition of enteric-coated capsules of comparative example 2

[0176] raw material Component (g) Capsules 636 (3000 tablets) Methacrylic acid copolymer 160.2 Triethyl citrate 24 Titanium Dioxide 16 Total 836.2 Theoretical coating weight gain 31.48%

[0177] Performance Test 2

[0178] 1. Acid resistance strength test

[0179] The acid resistance strength test of the present invention is determined according to the dissolution and release determination method (Chinese Pharmacopoeia 2020 Edition Four General Rules 0931 First Method), with hydrochloric acid solution (9→1000) 1000mL as the dissolution medium, the rotation speed is 100 revolutions per minute, and after acid resistance for 1h, 2h, and 3h, the active ingredient content of the remaining balls in the dissolution cup is determined by ultraviolet-visible spectrophotometry, and the content is used to characterize the strength of acid resistance, that is, the greater the content, the stronger the acid resistance. The acid resistance strength test results of the lansoprazole enteric-coated capsules of Examples 5-7 and Comparative Example 2 are shown in Table 20.

[0180] Table 20: Comparison of acid resistance strength of lansoprazole enteric-coated capsules of Examples 5-7 and Comparative Example 2

[0181]

[0182] It can be seen from Table 20 that although the capsules of Examples 5 and 6 were slightly deformed after 3 hours of acid resistance, the capsules were not broken. Analysis of the reason may be that water entered through the pores of the enteric film, causing the capsule shell to dissolve slightly. From the acid resistance data, the acid resistance of Examples 5-7 and Comparative Example 2 is very good.

[0183] 2. Dissolution rate test

[0184] Determination of Examples 5-7, Comparative Example 2 and The dissolution results at different times are shown in Table 21.

[0185] Table 21: Lansoprazole enteric-coated capsules of Examples 5-7 and Comparative Example 2 and Dissolution rate comparison table

[0186]

[0187] As shown in Table 21, the dissolution rate of Comparative Example 2 is slow and the dissolution platform is low due to the excessive coating weight gain. Compared with the preparation, the release speed is faster and can basically achieve complete release.

[0188] Example 8

[0189] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0190] The preparation process of the pills and capsule filling is the same as that in Example 5.

[0191] Capsule coating: (the weight gain ratio of triethyl citrate to methacrylic acid copolymer is 6%)

[0192] Triethyl citrate was added to purified water (233.63 g) and stirred to dissolve, and then titanium dioxide was added to uniformly disperse. The prepared solution was slowly added to a 30% (w / w) methacrylic acid copolymer aqueous dispersion solution (337.67 g), and sieved through 100 mesh to obtain a 20% (w / w) enteric coating solution. The capsule particles were put into a film coating machine, and the pot speed was set to 5-12 rpm, the air inlet temperature was 38-50° C., the air inlet frequency was 600-1500 Hz, the exhaust frequency was 600-1500 Hz, the atomization pressure was 0.3-0.8 bar, and the material temperature was maintained at 28-35° C. The enteric coating solution was evenly sprayed onto the surface of the capsule particles, and then dried at 45° C. for 30-60 min to obtain the lansoprazole enteric capsules of the present embodiment, and the raw material components thereof are shown in Table 22.

[0193] Table 22: Raw material composition of enteric-coated capsules of Example 8

[0194] raw material Component (g) Capsules 636 (3000 tablets) Methacrylic acid copolymer 101.3 Triethyl citrate 6.1 Titanium Dioxide 10.1 Total 753.5

[0195] Example 9

[0196] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0197] The preparation process of the pills and capsule filling is the same as that in Example 5.

[0198] Capsule coating: (the weight gain ratio of triethyl citrate to methacrylic acid copolymer is 10%)

[0199] Triethyl citrate was added to purified water (249.63 g) and stirred to dissolve, and then titanium dioxide was added to uniformly disperse. The prepared solution was slowly added to a 30% (w / w) methacrylic acid copolymer aqueous dispersion solution (337.67 g), and sieved through 100 mesh to obtain a 20% (w / w) enteric coating solution. The capsule particles were put into a film coating machine, and the pot speed was set to 5-12 rpm, the air inlet temperature was 38-50° C., the air inlet frequency was 600-1500 Hz, the exhaust frequency was 600-1500 Hz, the atomization pressure was 0.3-0.8 bar, and the material temperature was maintained at 28-35° C. The enteric coating solution was evenly sprayed onto the surface of the capsule particles, and then dried at 45° C. for 30-60 min to obtain the lansoprazole enteric-coated capsules of the present embodiment, and the raw material components thereof are shown in Table 23.

[0200] Table 23: Raw material composition of enteric-coated capsules of Example 9

[0201] raw material Component (g) Capsules 636 (3000 tablets) Methacrylic acid copolymer 101.3 Triethyl citrate 10.2 Titanium Dioxide 10.1 Total 762.6

[0202] Comparative Example 3

[0203] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0204] The preparation process of the pills and capsule filling is the same as that in Example 5.

[0205] Capsule coating: (the weight gain ratio of triethyl citrate to methacrylic acid copolymer is 3%)

[0206] Triethyl citrate was added to purified water (221.23 g) and stirred to dissolve, and then titanium dioxide was added to uniformly disperse. The prepared solution was slowly added to a 30% (w / w) methacrylic acid copolymer aqueous dispersion solution (337.67 g), and sieved through 100 mesh to obtain a 20% (w / w) enteric coating solution. The capsule particles were put into a film coating machine, and the pot speed was set to 5-12 rpm, the air inlet temperature was 38-50°C, the air inlet frequency was 600-1500 Hz, the exhaust frequency was 600-1500 Hz, the atomization pressure was 0.3-0.8 bar, and the material temperature was maintained at 28-35°C. The enteric coating solution was evenly sprayed onto the surface of the capsule particles, and then dried at 45°C for 30-60 min to obtain the lansoprazole enteric capsules of this comparative example, and the raw material components thereof are shown in Table 24.

[0207] Table 24: Raw material composition of enteric-coated capsules of comparative example 3

[0208] raw material Component (g) Capsules 636 (3000 tablets) Methacrylic acid copolymer 101.3 Triethyl citrate 3 Titanium Dioxide 10.1 Total 750.4

[0209] Comparative Example 4

[0210] A method for preparing lansoprazole enteric-coated capsules comprises the following steps:

[0211] The preparation process of the pills and capsule filling is the same as that in Example 5.

[0212] Capsule coating: (the weight gain ratio of triethyl citrate to methacrylic acid copolymer is 20%)

[0213] Triethyl citrate was added to purified water (290.43 g) and stirred to dissolve, and then titanium dioxide was added to uniformly disperse. The prepared solution was slowly added to a 30% (w / w) methacrylic acid copolymer aqueous dispersion solution (337.67 g), and sieved through 100 mesh to obtain a 20% (w / w) enteric coating solution. The capsule particles were put into a film coating machine, and the pot speed was set to 5-12 rpm, the air inlet temperature was 38-50°C, the air inlet frequency was 600-1500 Hz, the exhaust frequency was 600-1500 Hz, the atomization pressure was 0.3-0.8 bar, and the material temperature was maintained at 28-35°C. The enteric coating solution was evenly sprayed onto the surface of the capsule particles, and then dried at 45°C for 30-60 min to obtain the lansoprazole enteric capsules of this comparative example, and the raw material components thereof are shown in Table 25.

[0214] Table 25: Raw material composition of enteric-coated capsules of comparative example 4

[0215]

[0216]

[0217] Performance Test 3

[0218] 1. Acid resistance strength and coating effect test

[0219] According to the dissolution and release determination method (Chinese Pharmacopoeia 2020 Edition Four General Rules 0931 First Method), 1000mL of hydrochloric acid solution (9→1000) was used as the dissolution medium, the rotation speed was 100 revolutions per minute, and after 2 hours of acid resistance, the active ingredient content of the remaining balls in the dissolution cup was determined by ultraviolet-visible spectrophotometry, and the content was used to characterize the strength of acid resistance, that is, the greater the content, the stronger the acid resistance. The acid resistance strength of the lansoprazole enteric-coated capsules of Examples 6, 8-9 and Comparative Examples 3-4 was determined, and the appearance of the capsules was visually inspected to evaluate whether there were obvious defects on the capsule surface. The test results are shown in Table 26.

[0220] Table 26: Comparison of the acid resistance and coating effect of lansoprazole enteric-coated capsules of Examples 6, 8-9 and Comparative Examples 3-4

[0221]

[0222] As shown in Table 26, the TEC dosage from 6% to 15% of the polymer weight gain has little effect on acid resistance; when the TEC dosage is 20%, the coating process is more likely to stick to the pan, resulting in a small part of the capsule breaking or collapsing; at the same time, since the plasticizer is also a pore-forming agent in the enteric layer, too high a dosage has a certain impact on the acid resistance of the finished preparation. When the TEC dosage is 3%, the insufficient amount of plasticizer causes the coating film to be loose and the acid resistance is unqualified.

[0223] 2. Dissolution rate test

[0224] The dissolution rates of Examples 6, 8-9 and Comparative Examples 3-4 at different times were measured. The test results are shown in Table 27.

[0225] Table 27: Comparison of dissolution rates of lansoprazole enteric-coated capsules of Examples 6, 8-9 and Comparative Examples 3-4

[0226]

[0227]

[0228] It can be seen from Table 27 that when the TEC dosage is between 3% and 15%, the dissolution rate of the enteric-coated capsules is similar with no significant difference; when the TEC dosage reaches 20%, the dissolution is much faster, which may be due to the excessive amount of plasticizer, resulting in a significant pore-forming effect.

[0229] Example 10

[0230] This example investigates the effect of different pan speeds on the capsule coating effect, taking the appearance after coating and the coating efficiency as evaluation indicators. The raw material components of the capsule coating refer to Example 8, and the process parameters are investigated as follows:

[0231] Put the capsule particles into the film coating machine, set the pot speed to 5-20rpm, the inlet air temperature to 38-50℃, the inlet air frequency to 600-1500Hz, the exhaust air frequency to 600-1500Hz, the atomization pressure to 0.5bar, and the material temperature to 28-35℃. Spray the enteric coating solution evenly onto the surface of the capsule particles, and then dry them at 45℃. After drying, calculate the actual coating efficiency. The specific process parameters are shown in Table 28.

[0232] Table 28: Capsule coating process parameters of Example 10

[0233] Experiment number GZ-1 GZ-2 GZ-3 GZ-4 GZ-5 GZ-6 Pan speed rpm 5 7 10 12 15 20 Inlet air temperature ℃ 38-50 38-50 38-50 38-50 38-50 38-50 Air intake frequency Hz 1200 1200 1200 1200 1200 1200 Exhaust frequency Hz 1200 1200 1200 1200 1200 1200 Atomization pressure bar 0.5 0.5 0.5 0.5 0.5 0.5 Material temperature ℃ 28-35 28-35 28-35 28-35 28-35 28-35 Drying temperature℃ 45 45 45 45 45 45

[0234] After coating, 20 capsules were randomly sampled and the coating appearance of the capsules was observed under a black background. The actual coating efficiency was calculated. The results are shown in Table 29.

[0235] Table 29: Comparison of coating appearance and coating efficiency at different pan speeds

[0236]

[0237]

[0238] It can be seen from Table 29 that the pan speed has a significant effect on capsule coating. When the pan speed is between 5-15rpm, the capsule coating efficiency is greater than 80%. Although a small number of capsules of GZ-1 and GZ-5 have defects, it is still acceptable. When the pan speed is 20rpm, more capsules have serious edge grinding and the coating efficiency decreases.

[0239] Embodiment 11

[0240] This example investigates the effect of different air inlet frequencies / exhaust frequencies on the capsule coating effect, taking the appearance after coating and the coating efficiency as evaluation indicators. The components of the capsule coating refer to Example 8, and the process parameters are investigated as follows:

[0241] The capsules were put into the film coating machine, the pan speed was set to 10 rpm, the air inlet temperature to 38-50°C, the air inlet frequency to 600-1500 Hz, the exhaust frequency to 600-1500 Hz, the atomization pressure to 0.5 bar, the material temperature to 28-35°C, the enteric coating solution was evenly sprayed onto the surface of the capsules, and then dried at 45°C. After drying, the actual coating efficiency was calculated, and the specific process parameters are shown in Table 30.

[0242] Table 30: Capsule coating process parameters of Example 11

[0243] Experiment number JF-1 JF-2 JF-3 JF-4 JF-5 Pan speed rpm 10 10 10 10 10 Inlet air temperature ℃ 38-50 38-50 38-50 38-50 38-50 Air intake frequency Hz 600 800 1000 1200 1500 Exhaust frequency Hz 600 800 1000 1200 1500 Atomization pressure bar 0.5 0.5 0.5 0.5 0.5 Material temperature ℃ 28-35 28-35 28-35 28-35 28-35 Drying temperature℃ 45 45 45 45 45

[0244] After coating, 20 capsules were randomly sampled and the coating appearance of the capsules was observed under a black background. The actual coating efficiency was calculated. The results are shown in Table 31.

[0245] Table 31: Comparison of coating appearance and coating efficiency at different air inlet frequency / exhaust frequency

[0246]

[0247] It can be seen from Table 31 that when the air inlet frequency / exhaust frequency is between 800-1200Hz, the capsule coating efficiency is greater than 80%; when the air inlet frequency / exhaust frequency is 600Hz, the drying rate is insufficient, which easily causes the capsule shell to become sticky; when the air inlet frequency / exhaust frequency is 1500Hz, the drying speed is too fast, the coating efficiency is low, and the capsule surface is obviously rough.

[0248] Example 12

[0249] This example investigates the effect of different atomization pressures on capsule coating, taking the appearance after coating and coating efficiency as evaluation indicators. The components of capsule coating refer to Example 8, and the process parameters are investigated as follows:

[0250] Put the capsule particles into the film coating machine, set the pot speed to 10rpm, the inlet air temperature to 38-50℃, the inlet air frequency to 600-1500Hz, the exhaust air frequency to 600-1500Hz, the atomization pressure to 0.2-1.2bar, and the material temperature to 28-35℃. Spray the enteric coating solution evenly onto the surface of the capsule particles, and then dry them at 45℃. After drying, calculate the actual coating efficiency. The specific process parameters are shown in Table 32.

[0251] Table 32: Capsule coating process parameters of Example 12

[0252] Experiment number WH-1 WH-2 WH-3 WH-4 Pan speed rpm 10 10 10 10 Inlet air temperature ℃ 38-50 38-50 38-50 38-50 Air intake frequency Hz 1000 1000 1000 1000 Exhaust frequency Hz 1000 1000 1000 1000 Atomization pressure bar 0.2 0.8 1.0 1.2 Material temperature ℃ 28-35 28-35 28-35 28-35 Drying temperature℃ 45 45 45 45

[0253] After coating, 20 capsules were randomly sampled and the coating appearance of the capsules was observed under a black background. The actual coating efficiency was calculated. The results are shown in Table 33.

[0254] Table 33: Comparison of coating appearance and coating efficiency at different atomization pressures

[0255]

[0256] It can be seen from Table 33 that an atomization pressure of 1.2 bar easily causes the coating liquid to be sprayed onto the inner wall of the coating pan, and at the same time, the capsule particles flip violently and the spraying is uneven.

[0257] Example 13

[0258] This example investigates the effect of different material temperatures on the capsule coating effect, taking the appearance after coating, coating efficiency and acid resistance as evaluation indicators. The components of the capsule coating refer to Example 8, and the process parameters are investigated as follows:

[0259] The capsules were put into the film coating machine, and the pan speed was set to 10 rpm, the air inlet temperature to 38-50°C, the air inlet frequency to 600-1500 Hz, the exhaust frequency to 600-1500 Hz, the atomization pressure to 0.5 bar, and the material temperature to 25-28°C (target 26°C), 28-31°C (target 30°C), 32-35°C (target 34°C), 35-40°C (target 38°C). The enteric coating solution was evenly sprayed onto the surface of the capsules, and then dried at 45°C. After drying, the actual coating efficiency was calculated, and the specific process parameters are shown in Table 34.

[0260] Table 34: Capsule coating process parameters of Example 13

[0261]

[0262] After coating, 20 capsules were randomly sampled and the coating appearance of the capsules was observed under a black background. The actual coating efficiency was calculated. The results are shown in Table 35.

[0263] Table 35: Comparison of coating appearance and coating efficiency at different material temperatures

[0264]

[0265] The acid resistance strength of the material at different temperatures was measured, and the results are shown in Table 36.

[0266] Table 36: Comparison of acid resistance at different material temperatures

[0267]

[0268]

[0269] It can be seen from Table 36 that when the material temperature is less than 28°C, the capsule coating effect is very poor; when the material temperature is 28-31°C (target 30°C), 32-35°C (target 34°C), 35-40°C (target 38°C), the coating effect is good and the acid resistance is qualified.

[0270] Performance Test 4: Process Reproducibility

[0271] The raw material components of capsule coating refer to Example 8, and the capsule coating process parameters are set as shown in Table 37. Three batches of samples were prepared continuously to investigate the reproducibility of the capsule coating process of the present invention.

[0272] Table 37: Capsule coating process parameters for 3 batches of samples

[0273] Experiment number CX-1 CX-2 CX-3 Pan speed rpm 10 10 10 Inlet air temperature ℃ 38-50 38-50 38-50 Air intake frequency Hz 1000 1000 1000 Exhaust frequency Hz 1000 1000 1000 Atomization pressure bar 0.5 0.5 0.5 Material temperature ℃ 28-35 28-35 28-35 Drying temperature℃ 45 45 45

[0274] 1. Coating effect test

[0275] After coating, 20 capsules were randomly sampled and the coating appearance of the capsules was observed under a black background. The actual coating efficiency was calculated. The results are shown in Table 38.

[0276] Table 38: Comparison of coating appearance and coating efficiency of 3 batches of samples

[0277]

[0278] 2. Acid resistance strength test

[0279] The acid resistance strength of three batches of samples was measured and the results are shown in Table 39.

[0280] Table 39: Comparison of acid resistance of 3 batches of samples

[0281]

[0282]

[0283] 3. Dissolution rate test

[0284] The dissolution rates of three batches of samples were measured at different times. The results are shown in Table 40.

[0285] Table 40: Comparison of dissolution rates of 3 batches of samples

[0286] Test items CX-1 CX-2 CX-3 5min dissolution% 0 0 0 10min dissolution% 34 36 36 Dissolution% in 15 minutes 65 63 64 20min dissolution% 82 82 81 30min dissolution % 95 93 93 45min dissolution% 95 95 96

[0287] It can be seen from Tables 38-40 that the process of the present invention has good reproducibility.

[0288] For ordinary technicians in the technical field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, without having to go through creative labor. Therefore, simple improvements made to the present invention by those skilled in the art based on the disclosure of the present invention should be within the protection scope of the present invention. The above embodiments are preferred embodiments of the present invention, and all processes similar to the present invention and equivalent changes made should belong to the protection scope of the present invention.

Claims

1. A lansoprazole enteric-coated capsule, characterized in that: The method comprises a drug-containing pill, a capsule shell and an enteric coating; the drug-containing pill is filled in the capsule shell to form a capsule particle; and the enteric coating is coated on the surface of the capsule particle; The capsule shell is a hydroxypropyl methylcellulose capsule shell, and the raw material components of the enteric coating include, by weight: 24.13-43.37 parts of enteric coating material, 1.45-6.50 parts of plasticizer, and 2.41-4.34 parts of titanium dioxide; the mass ratio of the plasticizer to the enteric coating material is 6-15%; The enteric coating material is selected from any one of methacrylic acid copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl phthalate, and styrene maleic acid copolymer; the plasticizer is selected from any one of polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 8000, triethyl citrate, and triethyl glycerol; The lansoprazole enteric-coated capsules are prepared by a preparation method comprising the following steps: (1) preparing a pill containing the drug; (2) filling the drug-containing pills into a hydroxypropylmethylcellulose capsule shell to obtain capsule particles; (3) After the plasticizer is dissolved, titanium dioxide is added to disperse it, and then added to the aqueous dispersion solution of the enteric coating material, sifted to obtain an enteric coating solution; the enteric coating solution is sprayed onto the surface of the capsule particles for capsule coating, and dried to obtain the lansoprazole enteric capsules; During the capsule coating process, the pan speed is 5-15 rpm, the air inlet frequency / exhaust frequency is 600-1500 Hz, the atomization pressure is 0.2-1.0 bar, and the material temperature is 28-40°C.

2. The lansoprazole enteric-coated capsule according to claim 1, characterized in that: The raw material components containing the pills include, by weight: 30 parts of lansoprazole, 50-100 parts of sucrose pill cores, 20-60 parts of sucrose powder, 5-15 parts of corn starch, 10-30 parts of pH regulators, and 10-30 parts of low-substituted hydroxypropyl cellulose.

3. The lansoprazole enteric-coated capsule according to claim 2, characterized in that: The particle size of the sucrose pellet core is in the range of 0.5-1.0 mm.

4. The lansoprazole enteric-coated capsule according to claim 2, characterized in that: The pH regulator is selected from any one of sodium carbonate, sodium bicarbonate, light magnesium carbonate, heavy magnesium carbonate, sodium hydroxide, disodium hydrogen phosphate, and potassium hydrogen phosphate.

5. A method for preparing lansoprazole enteric-coated capsules, characterized in that: The preparation method is used to prepare the lansoprazole enteric-coated capsules according to any one of claims 1 to 4, comprising the following steps: (1) preparing a pill containing the drug; (2) filling the drug-containing pills into a hydroxypropylmethylcellulose capsule shell to obtain capsule particles; (3) After the plasticizer is dissolved, titanium dioxide is added to disperse it, and then added to the aqueous dispersion solution of the enteric coating material, sifted to obtain an enteric coating solution; the enteric coating solution is sprayed onto the surface of the capsule particles for capsule coating, and dried to obtain the lansoprazole enteric capsules; During the capsule coating process, the pan speed is 5-15 rpm, the air inlet frequency / exhaust frequency is 600-1500 Hz, the atomization pressure is 0.2-1.0 bar, and the material temperature is 28-40°C.

Citation Information

Patent Citations

  • Granules containing acid-unstable chemical in large amount

    CN100562317C

  • Method for preparing lansoprazole intestine dissolving capsule

    CN100574759C

  • Enteric-coated pellet preparation of proton pump inhibitor and preparation method thereof

    CN102119927B

  • Proton pump inhibitor enteric coated pellet and preparation and preparation method thereof

    CN103356489B

  • Solid pharmaceutical compositions containing proton pump inhibitors

    CN103381268B